science2 publishers
Novo unveils twelve more GLP-1 and amylin launches through 2030 as 2032 patent cliff looms
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
- Evidence64
- Adoption34
- Hype gap+24
- Incentives80
- Confidence67